Loading quotes...

Forecast

The analysts' average price target is €4.48 (+154.55%). The median is €4.48 (+154.55%).

Buy	14
Hold	0
Sell	1

News Go to news feed

Compugen presents data on COM701 as maintenance therapy for ovarian cancer at ESMO

At the ESMO congress, Compugen presented poster data from the ongoing adaptive MAIA‑ovarian study of the anti‑PVRIG antibody COM701, which is being investigated as maintenance therapy for recurrent, platinum‑sensitive ovarian cancer. According to the company, COM701 is well tolerated and has already shown consistent, durable response rates in heavily pretreated, platinum‑resistant patients. First data from the MAIA‑ovarian study are expected by the first quarter of 2027. » More on de.investing.com
Compugen presents MAIA‑ovarian phase 1 poster on COM701 at ESMO

On June 18 at the ESMO Congress in Copenhagen, Compugen will present a poster on the ongoing MAIA‑ovarian study, a blinded, randomized, adaptive platform trial evaluating COM701 as maintenance therapy for recurrent, platinum‑sensitive ovarian cancer. COM701 is an anti‑PVRIG antibody in clinical development; Dr. Oladapo Yeku of Massachusetts General Hospital will deliver the presentation. The poster will be available on Compugen’s website after the conference. According to published data, Compugen has multiple clinical programs, a positive liquidity position and a market capitalization of about $190 million. » More on de.investing.com
Compugen on track for COM701 interim PFS in Q1 2027, cash runway into 2029

Compugen said all sites are open and enrolling in the MAIA-ovarian trial for COM701 and remains on schedule to report interim progression-free survival data in the first quarter of 2027. The company highlighted advancing partnered programs, with AstraZeneca expanding rilvegostomig across multiple phase 3 trials and Gilead’s GS-0321 in phase 1 dose escalation. Compugen ended Q1 2026 with about $134.9 million in cash and investments, reported revenue of $2.2 million and a net loss of $7.7 million, and expects its cash position to fund operations into 2029. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 1998, Compugen has already paid €0.18 in dividends. The last payout was in July 1998.

Financials

In the last quarter, Compugen had revenue of €2.28m and net profit of -€6.14m

(EUR)	June 2026	YoY
Revenue	2.28m	113.78%
Gross profit	-80.61k	76.71%
Net profit	-6.14m	1.45%
EBITDA	-6.13m	1.78%

Fundamentals

Metric	Value
Market capitalization	€166.5m
Number of shares	94.72m
52-week high/low	€2.91 - €1.28
Dividends	No
Beta	2.82
P/E ratio	5.22
PEG ratio	0.06
P/B ratio	2.09
P/S ratio	2.51

Company profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.